US pharma major Merck (NYSE: MRK) is trying to make its looming Keytruda (pembrolizumab) patent hill look more like a speed ...
GlobalData on MSN
JPM26: MSD homes in on derisking strategy amid Keytruda patent cliff
MSD awaits 20 potential launches and 80 late-stage readouts across its pipeline, which it believes will double $35bn ...
Moderna pivots to infectious disease & oncology, targeting cash break-even by 2028. Click here to see why I rate MRNA stock a ...
13d
Merck: A Pharma Giant Trading At A Decade-Low Valuation While Executing Its Post-Keytruda Playbook
Merck (MRK) looks undervalued amid 2028 Keytruda patent fears—strong Q3 results, pipeline wins, and 12x P/E suggest upside.
RAHWAY, N.J., November 21, 2025--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved ...
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced new long-term data highlighting the sustained survival benefits of KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 ...
RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced positive topline results from the Phase 3 KEYNOTE-B15 trial (also known as EV-304) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback